What is Paradromics?
Paradromics is at the forefront of developing sophisticated brain-computer interface (BCI) solutions designed to address the profound communication challenges faced by individuals with severe paralysis. Their core technology, exemplified by the Connexus system, empowers those unable to speak to interact with digital devices through neural signals. The company is also advancing its Tempo product, which is geared towards monitoring brain states for mental health applications. By employing high-resolution brain activity recording coupled with advanced AI algorithms, Paradromics translates complex neural data into actionable health insights, targeting a broad spectrum of neurological and mental health conditions. Their commitment lies in creating scalable and enduring neurotechnology to serve the millions with unmet medical needs.
How much funding has Paradromics raised?
Paradromics has raised a total of $61.3M across 5 funding rounds:
Debt
$985K
Angel/Seed
$7M
Debt
$350K
Angel/Seed
$20M
Other Financing Round
$33M
Debt (2015): $985K, investors not publicly disclosed
Angel/Seed (2018): $7M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Angel/Seed (2021): $20M featuring Synergy Ventures, Westcott, Prime Movers Lab, IT Farm, Dolby Family Ventures, Alpha Edison, and Pureland Group
Other Financing Round (2023): $33M backed by Dolby Family Ventures, Green Sands Equity, and Westcott
Key Investors in Paradromics
Dolby Family Ventures
Dolby Family Ventures is an investment firm focused on supporting early-stage companies that address significant science and engineering challenges, particularly in the biotech and pharmaceutical sectors. Since its inception in 2014, the firm has prioritized investments in precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech.
Green Sands Equity
Green Sands Equity is a boutique private equity investment firm that focuses on Growth Equity investments in Technology and Healthcare companies at all stages. Headquartered in San Francisco, with additional offices in Zurich, Doha, Dubai, New York, and Singapore, the firm also provides advisory services to governments on policy strategy and foreign direct investment.
Synergy Ventures
Synergy Ventures provides medical device companies with timely access to the Japan market through our sister consulting company Synergy Partners International. Synergy has established a strong reputation in the venture capital and entrepreneur community for efficient and strategic assistance in negotiating and structuring Japan corporate relationships.
What's next for Paradromics?
The substantial enterprise-level backing, highlighted by the recent major strategic investment, positions Paradromics for significant expansion and technological advancement. This infusion of capital is anticipated to fuel further research and development, enhance manufacturing capabilities for their BCI devices, and broaden market penetration. The company's focus on both restoring communication and advancing mental health monitoring suggests a strategic diversification of its neurotechnology applications. With a clear trajectory from early-stage seed funding to more substantial rounds, Paradromics is demonstrating a maturation phase, likely aimed at scaling operations and achieving wider clinical adoption. Future developments will likely center on refining their AI algorithms, expanding the range of neurological conditions addressed, and solidifying partnerships within the healthcare and technology sectors.
See full Paradromics company page
